Medical device company Artivion (NYSE: AORT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.3% year on year to $125.8 million. The company expects the full year’s revenue to be around $488 million, close to analysts’ estimates. Its non-GAAP profit of $0.13 per share was 34.5% above analysts’ consensus estimates.

Is now the time to buy Artivion? Find out by accessing our full research report, it’s free.

Company Overview

Formerly known as CryoLife until its 2022 rebranding, Artivion (NYSE: AORT) develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.

Revenue Growth

A company’s long-term sales performance can indicate its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Luckily, Artivion’s sales grew at a decent 11% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Artivion’s annualized revenue growth of 11.8% over the last two years aligns with its five-year trend, suggesting its demand was stable.

This quarter, Artivion reported year-on-year revenue growth of 11.3%, and its $125.8 million of revenue exceeded Wall Street’s estimates by 4.4%.

Looking ahead, sell-side analysts expect revenue to grow 8.4% over the next 12 months, a deceleration versus the last two years. Still, this projection is healthy and indicates the market sees success for its products and services.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Adjusted Operating Margin

Artivion was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 9.9% was weak for a healthcare business.

On the plus side, Artivion’s adjusted operating margin rose by 2.5 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming into its more recent performance, however, we can see the company’s margin has decreased by 2.5 percentage points on a two-year basis. If Artivion wants to pass our bar, it must prove it can expand its profitability consistently.

In Q2, Artivion’s breakeven margin was -0.2%, down 15.1 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Artivion’s EPS grew at an unimpressive 2.4% compounded annual growth rate over the last five years, lower than its 11% annualized revenue growth. However, its adjusted operating margin actually improved during this time, telling us that non-fundamental factors such as interest expenses and taxes affected its ultimate earnings.

Diving into the nuances of Artivion’s earnings can give us a better understanding of its performance. A five-year view shows Artivion has diluted its shareholders, growing its share count by 24.6%. This dilution overshadowed its increased operational efficiency and has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q2, Artivion reported adjusted EPS of $0.13, down from $0.24 in the same quarter last year. Despite falling year on year, this print easily cleared analysts’ estimates. Over the next 12 months, Wall Street expects Artivion’s full-year EPS to stay about the same, moving from $0.54 to $0.54.

Key Takeaways from Artivion’s Q2 Results

It was good to see Artivion beat analysts’ EPS expectations this quarter. We were also glad its revenue outperformed Wall Street’s estimates. Zooming out, we think this was a solid print. The stock remained flat at $26.76 immediately after reporting.

Artivion may have had a good quarter, but does that mean you should invest right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).